Boehringer Ingelheim is partnering with opnMe to develop novel preclinical models for immune checkpoint blockade resistant lung cancer.
Public source
Publisher name
Public post
Lung cancer is a heterogeneous disease with various driver mutations, histological representations, and treatment considerations. Capturing this complexity in preclinica…
Company
Boehringer Ingelheim
- Industry
- Pharmaceutical Manufacturing
- Location
- Ingelheim am Rhein, DE
- Company size
- 10,001+ employees
About Boehringer Ingelheim
Our people are our strength. And together with over 54,000 colleagues, we're creating the next breakthrough in the world of healthcare and innovation for both humans and animals. Are you ready to join us? #LifeForward Privacy Notice: https://www.boehringer-ingelheim.com/privacy-notice Imprint: https://www.boehringer-ingelheim.com/imprint
See moreLatest activity
Latest activity from Boehringer Ingelheim
43 signals
Products & Services
Boehringer Ingelheim offers BI-7828, a potent MDM2-p53 antagonist that reactivates p53 signaling in TP53 wild-type tumors.
Products & Services
Boehringer Ingelheim is inviting experts to propose bold concepts for an autonomous small-molecule synthesis platform encompassing the complete Make phase from reagent handling to delivery of purified compounds.
Products & Services
Boehringer Ingelheim offers BI-7828, a potent MDM2-p53 antagonist that reactivates p53 signaling in TP53 wild-type tumors.
Discover more
Similar signals
Similar public activity from other companies.
Partnerships
GSK
GSK entered into a new oncology partnership with Hutchmed to develop an investigational innovative dual-mechanism antibody-targeted therapy conjugate (ATTC) for pancreatic, colorectal, and lung cancers.
Partnerships
Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc. collaborated with Merck to evaluate INT230-6 in combination with KEYTRUDA in advanced solid malignancies.
Partnerships
Debiopharm
Debiopharm entered into a new partnership with DayOne - Healthtech Innovation, a non-profit accelerator supporting high-potential healthtech start-ups towards transforming pharma R&D.
Partnerships
AstraZeneca
AstraZeneca is working with partners to use data and evidence to identify underserved communities and target prevention, earlier diagnosis and treatment for lung cancer and COPD.
Partnerships
Redx Pharma